Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Galaxy Diagnostics commercializes highly sensitive molecular and serological assays for the direct detection of elusive vector-borne pathogens such as Bartonella, Borrelia, and Babesia. Their proprietary BAPGM™ enrichment medium combined with digital PCR enables superior sensitivity compared to conventional methods. The company’s tests are supported by peer-reviewed publications demonstrating improved clinical utility in detecting low-abundance infections that often evade standard diagnostics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Galaxy Diagnostics.